Mar 20, 2022
By Tushar Patel Vice President, US Sleep-Wake Commercial and Global Strategic Marketing, Neurology Business Group Each March, many Americans look forward to advancing our clocks by one hour as...
Jul 18, 2021Precision Solutions for Alzheimer’s Disease: Tailoring Specific Biological and Clinical Features of the Patient
Ivan Cheung, Chairman, Eisai Inc. and Global President, Neurology Business Group, Eisai Co., Ltd. & Harald Hampel, MD, PhD, Vice President, Chief Medical Officer, Neurology Business Group, Eisai Inc.
Jan 8, 2021
By Renee Campbell, MD, MBA, MPH, Global Value and Access Epilepsy and Sleep lead, Genevieve De Sousa Meier, Executive Director, Head of Global Value and Access, and Amir Abbas Tahami Monfared,...
Dec 17, 2020Higher Health Care Resource Use, Costs Associated With Falls Among Older Medicare Beneficiaries on Commonly Used Insomnia Medications in the United States
By Feride Frech, PhD, MPH, Senior Director, US HEOR & RWE, Eisai Inc, and Timothy Juday, Director, US HEOR & RWE, Eisai Inc. Insomnia, the most common sleep-wake disorder, is prevalent in the...
Feb 3, 2021The ATX(N) classification system and its potential use in clinical practice and therapy development for Alzheimer’s disease
Harald Hampel, MD, PhD Vice President, Chief Medical Officer, Neurology Business Group, Eisai Inc. Alzheimer’s disease (AD) is a devastating neurodegenerative disease. It is estimated to affect...